Biogen
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Established
- 1978-01-01
- Employees
- 7.5K
- Market Cap
- $29.6B
- Website
- https://www.biogen.com
- Introduction
Biogen, Inc. is a biopharmaceutical company, which engages in discovering, developing, and delivering therapies for neurological and neurodegenerative diseases. Its products include TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI and FAMPYRA for the treatment of MS, SPINRAZA for the treatment of SMA, ADUHELM for the treatment of Alzheimer's disease, and FUMADERM for the treatment of severe plaque psoriasis. The company was founded by Charles Weissmann, Heinz Schaller, Kenneth Murray, Walter Gilbert, and Phillip Allen Sharp in 1978 and is headquartered in Cambridge, MA.
Ophthalmology Times 2024 wrap-up: A year of innovation and insight
Ophthalmology Times reviewed 2024's key topics: AI's role in healthcare, VR for medical collaboration, OR efficiency, sustainability in surgeries, biosimilars for retinal diseases, and dry eye treatments. FDA approvals included new IOLs and biosimilars, marking advancements in eye care.
The Chase for Novel Oral GLP-1 Obesity Meds Adds a New Contender
Corxel Pharmaceuticals acquired VCT220, a Phase 2-ready oral GLP-1 agonist for obesity and diabetes, from Vincentage Pharma, excluding Greater China. Renamed CX11, it aims to offer a patient-friendly alternative to injectable GLP-1 drugs, with Phase 3 trials underway in China and global Phase 2 trials planned for 2025.
Cancer Immunotherapy Market Research Report 2025-2029
The Cancer Immunotherapy Market 2025-2029 report forecasts significant growth in immuno-oncology therapeutics, highlighting technologies like CAR-T Cells and Checkpoint Inhibitors. It offers insights into market opportunities, key players, and the impact on healthcare, aiming to guide investment and strategic decisions.
Red Biotechnology Market Growth, Trends & Key Players Analysis
The Red Biotechnology Market is projected to grow at a CAGR of 5.2% from 2024 to 2031, driven by advancements in genomics, personalized treatments, and chronic diseases. Key players include Hoffmann-La Roche, Merck KGaA, and Regeneron Pharmaceuticals.
2024 Highlights the Rollercoaster That Is Neuro
2024 saw highs and lows in neuroscience drug development, including FDA approval of BMS's Cobenfy for schizophrenia and Eli Lilly's donanemab for Alzheimer's, alongside failures like Sage Therapeutics' dalzanemdor in Parkinson's, Alzheimer's, and Huntington's. Despite setbacks, progress continues in treating intractable neurological diseases.
Fighting to Avoid Her Mother's Fate, for Her Daughters' Sake
Linde Jacobs, after discovering she inherited a gene causing frontotemporal dementia (FTD) from her mother, embarks on a mission to find a cure. Despite the grim prognosis, she connects with scientists, including Dr. Claire Clelland, exploring gene editing and treatments. Linde's advocacy and the scientific community's efforts offer hope for future therapies, as she navigates her life with the looming threat of FTD, aiming to protect her daughters from the same fate.
Ionis Gets FDA Approval for Rare Disease Drug Tryngolza
Ionis Pharmaceuticals' shares rose 5% after FDA approved its RNA-targeted therapy, Tryngolza, for familial chylomicronemia syndrome (FCS), marking the first treatment for FCS in the U.S. The approval is supported by phase III BALANCE study results showing significant triglyceride-lowering and reduced acute pancreatitis attacks. Tryngolza is Ionis' first wholly-owned drug and independent commercial launch, expected by year-end. The company is also evaluating Tryngolza for severe hypertriglyceridemia and has collaborations with major drugmakers for various treatments.
Roche's Parkinson's hope fails second clinical trial
Roche and Prothena's prasinezumab, targeting alpha-synuclein for Parkinson's, missed primary endpoint in phase 2b PADOVA trial but showed numerical delay in motor progression and positive trends on secondary endpoints. Roche plans further exploration and collaboration with Parkinson's community.
© Copyright 2025. All Rights Reserved by MedPath